Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism.
Details
Serval ID
serval:BIB_521B69BF3577
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism.
Journal
Internal and emergency medicine
Working group(s)
RIETE Investigators
Contributor(s)
Adarraga M.D., Aibar M.A., Alfonso M., Arcelus J.I., Ballaz A., Baños P., Barba R., Barrón M., Bascuñana J., Blanco-Molina A., Camon A.M., Carrasco C., Chasco L., Cruzs A.J., Del Pozo R., Del Toro J., Díaz-Pedroche M.C., Díaz-Peromingo J.A., Encabo M., Falgá C., Fernández-Aracil C., Fernández-Capitán C., Fidalgo M.A., Font C., Font L., Furest I., García M.A., García-Bragado F., García-Morillo M., García-Raso A., García-Sánchez I., Gavín O., Gómez C., Gómez V., González J., Grau E., Guijarro R., Guirado L., Gutiérrez J., Hernández-Blasco L., Hernando E., Isern V., Jara-Palomares L., Jaras M.J., Jiménez D., Joya M.D., Lima J., Llamas P., Lobo J.L., López-Jiménez L., López-Reyes R., López-Sáez J.B., Lorente M.A., Lorenzo A., Loring M., Lumbierres M., Madridano O., Maestre A., Marchena P.J., Martín M., Martín-Martos F., Mellado M., Monreal M., Morales M.V., Nieto J.A., Núñez M.J., Olivares M.C., Otalora S., Otero R., Pedrajas J.M., Pellejero G., Pérez-Ductor C., Peris M.L., Pons I., Porras J.A., Riera-Mestre A., Rivas A., Rodríguez-Dávila M.A., Rodríguez-Galán I., Rosa V., Rubio C.M., Ruiz-Artacho P., Sahuquillo J.C., Sala-Sainz M.C., Sampériz A., Sánchez-Artola B., Sánchez-Martínez R., Sancho T., Soler S., Soto M.J., Suriñach J.M., Tolosa C., Torres M.I., Trujillo-Santos J., Uresandi F., Usandizaga E., Valero B., Valle R., Vela J., Vidal G., Villalobos A., Xifre B., Vázquez F.J., Vilaseca A., Vanassche T., Vandenbriele C., Verhamme P., Yoo HHB, Wells P., Hirmerova J., Malý R., Salgado E., Benzidia I., Bertoletti L., Bura-Riviere A., Falvo N., Farge-Bancel D., Hij A., Merah A., Mahé I., Moustafa F., Quere I., Braester A., Brenner B., Ellis M., Tzoran I., Antonucci G., Bilora F., Bucherini E., Cattabiani C., Ciammaichella M., Dentali F., Di Micco P., Doddi M., Duce R., Giorgi-Pierfranceschi M., Grandone E., Imbalzano E., Lessiani G., Maggi F., Maida R., Mastroiacovo D., Pace F., Pesavento R., Poggio R., Prandoni P., Quintavalla R., Rocci A., Siniscalchi C., Tiraferri E., Tonello D., Visonà A., Zalunardo B., Gibietis V., Skride A., Vitola B., Zdraveska M., Bounameaux H., Calanca L., Fresa M., Mazzolai L., Bikdeli B.
ISSN
1970-9366 (Electronic)
ISSN-L
1828-0447
Publication state
Published
Issued date
10/2019
Peer-reviewed
Oui
Volume
14
Number
7
Pages
1101-1112
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
The association between inferior vena cava filter (IVC) use and outcome in patients presenting with major bleeding during anticoagulation for venous thromboembolism (VTE) has not been thoroughly investigated. We used the RIETE registry to compare the 30-day outcomes (death, major re-bleeding or VTE recurrences) in VTE patients who bled during the first 3 months of therapy, regarding the insertion of an IVC filter. A propensity score matched (PSM) analysis was performed to adjust for potential confounders. From January 2001 to September 2016, 1065 VTE patients had major bleeding during the first 3 months of anticoagulation (gastrointestinal 370; intracranial 124). Of these, 122 patients (11%) received an IVC filter. Patients receiving a filter restarted anticoagulation later (median, 4 vs. 2 days) and at lower doses (95 ± 52 IU/kg/day vs. 104 ± 55 of low-molecular-weight heparin) than those not receiving a filter. During the first 30 days after bleeding (after excluding 246 patients who died within the first 24 h), 283 patients (27%) died, 63 (5.9%) had non-fatal re-bleeding and 19 (1.8%) had recurrent pulmonary embolism (PE). In PSM analysis, patients receiving an IVC filter (n = 122) had a lower risk for all-cause death (HR 0.49; 95% CI 0.31-0.77) or fatal bleeding (HR 0.16; 95% CI 0.07-0.49) and a similar risk for re-bleeding (HR 0.55; 95% CI 0.23-1.40) or PE recurrences (HR 1.57; 95% CI 0.38-6.36) than those not receiving a filter (n = 429). In VTE patients experiencing major bleeding during the first 3 months, use of an IVC filter was associated with reduced mortality rates.Clinical Trial Registration NCT02832245.
Keywords
Aged, Aged, 80 and over, Anticoagulants/adverse effects, Anticoagulants/therapeutic use, Female, Hemorrhage/etiology, Humans, Male, Middle Aged, Registries/statistics & numerical data, Retrospective Studies, Risk Factors, Statistics, Nonparametric, Thromboembolism/drug therapy, Treatment Outcome, Vena Cava Filters/standards, Vena Cava Filters/statistics & numerical data, Anticoagulants, Bleeding, Mortality, Vena cava filter, Venous thromboembolism.
Pubmed
Web of science
Create date
26/11/2020 13:03
Last modification date
05/06/2021 6:33
Usage data
